Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01381770
Other study ID # plt-msl001
Secondary ID
Status Completed
Phase Phase 2
First received June 23, 2011
Last updated August 24, 2015
Start date September 2010
Est. completion date May 2013

Study information

Verified date August 2015
Source IRCCS Policlinico S. Matteo
Contact n/a
Is FDA regulated No
Health authority Italy: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate that platelet-derived repairing factors are effective and safe in the treatment of muscular lesion grade 2 or 3, a Phase II, open-label, single arm, single centre has been designed. Sample size will be 25.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date May 2013
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- age > 18 years old

- if woman, no pregnancy ongoing

- muscular lesion grade 2 or 3 in a lower limb muscular group

Exclusion Criteria:

- no hematological conditions

- no anticoagulation in the two preceding weeks

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
platelet-derived repairing factors
autologous platelet lysate injection within 24 hours from lesion

Locations

Country Name City State
Italy Clinica Ortopedica Fondazione IRCCS Policlinico San Matteo Pavia

Sponsors (1)

Lead Sponsor Collaborator
IRCCS Policlinico S. Matteo

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary number (and proportion with 95% CI) of patients able to return to sport activity (i.e. training) at 21 days from muscular injury. If the athlete is able, 21 days after the muscular injury, to return to (at least) training activities, the outcome will be coded "successful"; and "unsuccessful" otherwise 21 days from enrollment No
Secondary Time-to-return to sport activities within 4 months from lesion No
Secondary Side effects Overall frequency of patients with any adverse events (number, proportion and 95%CI) within 4 months from treatment Yes
Secondary time-to-healing at ultrasound within 4 months from treatment No
Secondary side effects types of side effects (number, proportion and 95%CI for each type of adverse events) within 4 months from treatment Yes
Secondary side effects grade of side effects (number, proportion and 95%CI for each grade of adverse events) within 4 months from treatment Yes